𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels

✍ Scribed by J. W. Shin; S. W. Jung; B. R. Park; C. J. Kim; J. B. Eum; B. G. Kim; I. D. Jeong; S.-J. Bang; S.-H. Lee; S. R. Kim; N. H. Park

Book ID
117947772
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
98 KB
Volume
19
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Early on-treatment prediction of respons
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

Prediction of the response to peg-interf
Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 193 KB πŸ‘ 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d